COL7A1 and recessive dystrophic epidermolysis bullosa: In this study, we developed a nanoinjection approach for base editing (nanoneedle editing) in vitro and applied it to correct a single nucleotide pathogenic variant (c.5047 C>T in COL7A1) causing RDEB in patient‐derived primary fibroblasts (Figure1a).